About this trial
The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.
Eligibility criteria
Qualifiers
Cohort 1
Have a radiologically, cytologically, or histologically confirmed diagnosis of cancer
Are treatment-naïve to a systemic cancer therapy, OR have a documented disease progression on standard-of-care treatment (for example, failure of chemotherapy, targeted therapy or immunotherapy)
Have at least 1 imageable tumor that is 15 millimeter (mm) or larger in the longest diameter
Disqualifiers
Are pregnant or intend to become pregnant during their participation in the study
Are breastfeeding or intending to breastfeed during their participation in the study
Have a history of risk factors for Torsades de Pointes (for example, heart failure, hypokalemia, family history of Long QT Syndrome)
Are actively receiving cancer therapy or are in between cycles of treatment
Trial design
Treatments tested in this trial
- LY4214835